+ HEALTH Rationale and objectives To propose a new imaging biomarker, the pulmonary artery-to-vein volume difference (…± HEALTH Rationale and objectives The international application of artificial intelligence (AI) for lesion detection b…± HEALTH Rationale and objectives To address the challenge of preoperative prediction of synchronous liver metastasis…± HEALTH Objectives To conduct a nationwide survey among professionals working in oncology departments in China to inv…+ HEALTH The utilization of deep convolutional neural networks for the purpose of diagnosing diseases in the skin area…± HEALTH BACKGROUND . Gadolinium-based contrast agents remain essential for MRI but carry risks. Deep learning (DL) me…+ SCIENCE Gas Chromatography is a versatile separation technique widely used in analytical chemistry for constituent de…+ HEALTH Background Intracardiac echocardiography (ICE) facilitates left atrial (LA) reconstruction during atrial fibr…
TruaceTracing the truth around AIThursday, August 27, 2026
Subscribe
Health·G Space·Evidence-backed gain·Published 2026-08-27

Pulmonary Artery-to-Vein Volume Difference: A New Imaging Biomarker for Risk Stratification in Acute Pulmonary Embolism

Abstract: Rationale and objectives To propose a new imaging biomarker, the pulmonary artery-to-vein volume difference (PAVVD), and evaluate its efficacy in risk stratification of acute pulmonary embolism (APE) compared with traditional computed tomography pulmonary angiography (CTPA) parameters, as well as the impact of chronic pulmonary disease (CPD). Materials and methods This retrospective study included 134 patients with APE (high/intermediate-high risk, n = 46; intermediate-low/low risk, n = 88) from April 2023 to Ma…

TRV-2026-0909Peer-reviewedPermanent record — cite & verify
Pulmonary Artery-to-Vein Volume Difference: A New Imaging Biomarker for Risk Stratification in Acute Pulmonary Embolism

"Pulmonary embolism CTPA" by Aung Myat and Arif Ahsan is licensed under CC BY 2.0. To view a copy of this license, visit https://creativecommons.org/licenses/by/2.0/.

The quick read

Researchers retrospectively analyzed 134 acute pulmonary embolism cases from April 2023 to March 2024, using commercial AI software to automatically measure a new biomarker, pulmonary artery-to-vein volume difference, alongside traditional CTPA parameters to stratify high/intermediate-high versus lower risk.

By the August 2026 publication date, the AI-derived PAVVD showed the strongest discriminative performance and net clinical benefit in low-to-moderate risk thresholds, suggesting utility as a complement to existing CTPA measures for emergency triage, though findings remain confined to a single retrospective cohort without prospective validation.

Main points
  • Retrospective study of 134 patients with APE from April 2023 to March 2024 compared PAVVD against traditional CTPA parameters.
  • Commercial AI software automatically quantified PAVVD, clot volume, and Qanadli score for analysis.
  • Decision curve analysis showed PAVVD yielded highest net benefit in low-to-moderate threshold probability range for emergency triage.
Gain

Automated AI quantification of pulmonary artery-to-vein volume difference achieved the highest discrimination for high/intermediate-high risk acute pulmonary embolism with low missed-diagnosis risk.

The rundown

The study evaluated 134 APE patients split into high/intermediate-high risk (n=46) and intermediate-low/low risk (n=88) using commercial AI to quantify PAVVD and traditional CTPA metrics, comparing performance via AUC, sensitivity, specificity, NPV, NLR, and decision curve analysis.

Results reported PAVVD AUC 0.89 (95% CI 0.83-0.95), NPV 0.94 and NLR 0.13 indicating lowest missed diagnosis risk, with a noted crossover effect versus clot volume related to Qanadli score and multivariate regression to assess influence of chronic pulmonary disease.

Sources

Reader signal

How should this claim be treated?

The debate